221 related articles for article (PubMed ID: 34451832)
1. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients.
Schotten C; Ostertag B; Sowa JP; Manka P; Bechmann LP; Hilgard G; Marquardt C; Wichert M; Toyoda H; Lange CM; Canbay A; Johnson P; Wedemeyer H; Best J
Pharmaceuticals (Basel); 2021 Jul; 14(8):. PubMed ID: 34451832
[TBL] [Abstract][Full Text] [Related]
2. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
Best J; Bechmann LP; Sowa JP; Sydor S; Dechêne A; Pflanz K; Bedreli S; Schotten C; Geier A; Berg T; Fischer J; Vogel A; Bantel H; Weinmann A; Schattenberg JM; Huber Y; Wege H; von Felden J; Schulze K; Bettinger D; Thimme R; Sinner F; Schütte K; Weiss KH; Toyoda H; Yasuda S; Kumada T; Berhane S; Wichert M; Heider D; Gerken G; Johnson P; Canbay A
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):728-735.e4. PubMed ID: 31712073
[TBL] [Abstract][Full Text] [Related]
3. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.
Best J; Bilgi H; Heider D; Schotten C; Manka P; Bedreli S; Gorray M; Ertle J; van Grunsven LA; Dechêne A
Z Gastroenterol; 2016 Dec; 54(12):1296-1305. PubMed ID: 27936479
[No Abstract] [Full Text] [Related]
4. Validation of the GALAD Model and Establishment of GAAP Model for Diagnosis of Hepatocellular Carcinoma in Chinese Patients.
Liu M; Wu R; Liu X; Xu H; Chi X; Wang X; Zhan M; Wang B; Peng F; Gao X; Shi Y; Wen X; Ji Y; Jin Q; Niu J
J Hepatocell Carcinoma; 2020; 7():219-232. PubMed ID: 33123501
[TBL] [Abstract][Full Text] [Related]
5. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States.
Tayob N; Kanwal F; Alsarraj A; Hernaez R; El-Serag HB
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):415-423.e4. PubMed ID: 35124267
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic performances of GALAD score in staging and 1-year mortality of hepatocellular carcinoma: A prospective study.
Jitpraphawan O; Ruamtawee W; Treewatchareekorn M; Sethasine S
World J Gastroenterol; 2024 May; 30(17):2343-2353. PubMed ID: 38813057
[TBL] [Abstract][Full Text] [Related]
7. ASAP Score
Liu SY; Li C; Sun LY; Guan MC; Gu LH; Yin DX; Yao LQ; Liang L; Wang MD; Xing H; Zhu H; Pawlik TM; Lau WY; Shen F; Tong XM; Yang T
Front Oncol; 2022; 12():1018396. PubMed ID: 36263214
[TBL] [Abstract][Full Text] [Related]
8. Comparison between models for detecting hepatocellular carcinoma in patients with chronic liver diseases of various etiologies: ASAP score versus GALAD score.
Sun LY; Wang NY; Diao YK; Yan CL; Fan ZP; Wei LH; Li HJ; Guan MC; Wang MD; Pawlik TM; Lau WY; Shen F; Lv GY; Yang T
Hepatobiliary Pancreat Dis Int; 2023 Dec; ():. PubMed ID: 38199909
[TBL] [Abstract][Full Text] [Related]
9. The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma.
Olbrich A; Niemeyer J; Seiffert H; Ebel S; Gros O; Lordick F; Forstmeyer D; Seehofer D; Rademacher S; Denecke T; Matz-Soja M; Berg T; van Bömmel F
J Cancer Res Clin Oncol; 2024 Feb; 150(2):81. PubMed ID: 38319485
[TBL] [Abstract][Full Text] [Related]
10. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection.
Caviglia GP; Abate ML; Petrini E; Gaia S; Rizzetto M; Smedile A
Hepatol Res; 2016 Mar; 46(3):E130-5. PubMed ID: 26082262
[TBL] [Abstract][Full Text] [Related]
11. Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients.
Li L; Lu F; Chen P; Song H; Xu W; Guo J; Wang J; Zhou J; Kang X; Jin C; Cai Y; Feng Z; Gao H
Front Oncol; 2022; 12():1037742. PubMed ID: 36620588
[TBL] [Abstract][Full Text] [Related]
12. Validation and optimization of AFP-based biomarker panels for early HCC detection in Latin America and Europe.
Beudeker BJB; Fu S; Balderramo D; Mattos AZ; Carrera E; Diaz J; Prieto J; Banales J; Vogel A; Arrese M; Oliveira J; Groothuismink ZMA; van Oord G; Hansen BE; de Man RA; Debes JD; Boonstra A
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37708457
[TBL] [Abstract][Full Text] [Related]
13. Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysis.
Li H; Liu H; Yan LJ; Ding ZN; Zhang X; Pan GQ; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Yan YC; Li T
Expert Rev Gastroenterol Hepatol; 2023; 17(11):1159-1167. PubMed ID: 37929312
[TBL] [Abstract][Full Text] [Related]
14. Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC.
Huang C; Xiao X; Zhou L; Chen F; Wang J; Hu X; Gao C;
J Clin Lab Anal; 2023 Dec; 37(23-24):e24990. PubMed ID: 38063322
[TBL] [Abstract][Full Text] [Related]
15. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
16. Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) based on gender, age, multitarget circulating tumour DNA methylation signature and commonly used serological biomarkers for early detection of hepatocellular carcinoma: a multicentre, prospective observational study protocol.
Yang T; Wang N; Wang F; Liu H; Shen F; Lv G
BMJ Open; 2023 Sep; 13(9):e076467. PubMed ID: 37723113
[TBL] [Abstract][Full Text] [Related]
17. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study.
Huang C; Fang M; Xiao X; Wang H; Gao Z; Ji J; Liu L; Gu E; Li Y; Wang M; Gao C
Liver Int; 2022 Jan; 42(1):210-223. PubMed ID: 34679250
[TBL] [Abstract][Full Text] [Related]
18. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
[TBL] [Abstract][Full Text] [Related]
20. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.
Berhane S; Toyoda H; Tada T; Kumada T; Kagebayashi C; Satomura S; Schweitzer N; Vogel A; Manns MP; Benckert J; Berg T; Ebker M; Best J; Dechêne A; Gerken G; Schlaak JF; Weinmann A; Wörns MA; Galle P; Yeo W; Mo F; Chan SL; Reeves H; Cox T; Johnson P
Clin Gastroenterol Hepatol; 2016 Jun; 14(6):875-886.e6. PubMed ID: 26775025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
